Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 47 for “"Castrate Resistant Prostate Cancer"”.
-
Characterisation of Docetaxel-Resistance in Castrate Resistant Prostate Cancer
Prostate cancer remains the third leading cause of cancer death in men in the developed world with metastatic castrate resistant prostate cancer (CRPC) being the lethal stage of the disease. Docetaxel-based chemotherapy is the standard-of-care for CRPC patients. Inevitably, those patients who …
-
Chemical Investigations of Diabetes Mellitus, Malaria, and Castrate-Resistant Prostate Cancer
… and treatment of diabetes mellitus, malaria, and castrate resistant prostate cancer. The first system studied, diabetes mellitus, involves synthesis of 5 different steroidal compounds, while the other two systems, malaria and castrate-resistant prostate cancer, apply mass spectrometric-based …
-
Nitroreductase suicide gene and immunotherapy in locally relapsed, castrate resistant prostate cancer
… the efficacy of a new adenoviral construct in prostate cancer cell lines in preparation for a gene and immunotherapy clinical trial in prostate cancer. By demonstrating the constructs ability to infect prostate cancer cells and cause them to die with the introduction of the prodrug, CB1954 as …
-
A lifestyle intervention to improve outcomes in men with castrate-resistant prostate cancer
… a useful supportive therapy for men with prostate cancer, improving physiological and psychosocial outcomes. There has been limited investigation of the effects of such interventions in men with castrate resistant prostate cancer (CRPC), the terminal phase of the disease. It is not clear …
-
Examining the potential links between Inhibitory ?B Kinases and Androgen receptors in castrate resistant prostate cancer
Prostate cancer is one of the most common cancers which affect men. The cancer progresses in two stages: hormone naïve prostate cancer (HNPC) to castrate resistant prostate cancer (CRPC); a common theme surrounding prostate cancer is the increased expression of the Androgen receptor (AR). The NF-?B …
-
CLINICAL AND LABORATORY CHARACTERISTICS THAT INFLUENCE PROGNOSIS OF MEN WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER TREATED WITH RADIUM-223
… distributed into high turnover bone affected by cancer cells after intravenous administration. It has been shown to reduce mortality in patients with boney metastases due to metastatic castration-resistant prostate cancer (mCRPC). However, which patients benefit most from radium-223 therapy …
-
The interaction between the PI3K/Akt cascade and the androgen receptor in the development and progression of castrate resistant prostate cancer
Prostate cancer has high cancer incidence in males and is the second highest cause of male cancer related mortality. Currently the main stay therapy for localised and metastatic disease is maximum androgen blockade (MAB). This aims to inhibit androgen production or action, thereby reducing …
-
Understanding the mechanism of 177Lu- PSMA617 radioligand therapy and evaluating its potential role in the treatment of metastatic castrate resistant prostate cancer (mCRPC)
Prostate cancer is the most common cancer in men and the third leading cause of cancer-related deaths in Canadian men. Despite hormone and radiation therapies, most patients progress to late-stage metastatic castrate-resistant prostate cancer (mCRPC). 177Lu-PSMA617 radioligand therapy (rLT) is a …
-
Επιλογές θεραπείας στον ορμονοάντοχο καρκίνο του προστάτη
… ασθενών με ορμονοάντοχο καρκίνο του προστάτη. (castrate- resistant prostate cancer). Στην εργασία αυτή αναλύονται θεραπείες, οι οποίες έχουν επιβεβαιωθεί σε μεγάλες κλινικές μελέτες φάσεως 2 και 3. Ως θεραπείες πρώτης γραμμής θεωρούνται ο ανδρογονικός αποκλεισμός, τα μοντέρνα αντι- ανδρογόνα …
-
Proteomics-Driven In Vitro Prediction of Drug Sensitivity
Predicting cancer drug sensitivity remains a critical challenge in precision oncology. This study develops a proteomics-based predictive model using ProCan-DepMapSanger protein expression data as the training dataset and non-normalized area under the dose-response curve (AUC) values from the …
-
Η μελέτη του μικροπεριβάλλοντος στον καρκίνο προστάτη
… the roles of MET and VEGFR2 as targets for prostate cancer therapy.EXPERIMENTAL DESIGN:In the clinical trial, radiographic imaging and serum markers were examined, as well as molecular markers in tumors from bone biopsies. In mice harboring PDX intrafemurally or subcutaneously, cabozantinib …
-
Diethylstilbestrol Nanosuspensions for Prostate Cancer: Subcutaneous Sustained Release Formulations and Pre-clinical PK/PD Evaluations
Prostate cancer is the most common type of cancer and the second leading cause of cancer related deaths in men in the United States. According to the National Cancer Institute (NCI), 238,590 new cases with deaths of 29,720 from prostate cancer have been estimated for 2013. Diethylstilbestrol (DES) …
-
AMPK Activation by Zyflamend: A novel pathway regulating metabolism and growth in prostate cancer
… tumor growth using preclinical models of castrate-resistant prostate cancer (CR-PCa), mediated in part by activating AMPK, a master energy sensor of the cell. Currently, two predominant upstream kinases are known to phosphorylate/activate AMPK at Thr172: LKB1, a known tumor suppressor, and …
-
Altered calcium signalling in prostate cancer facilitates progression to castrate resistance
Prostate cancer (PCa) carries a significant clinical burden worldwide with ~1.3-million new cases annually. It is the most frequently diagnosed cancer in Irish men, excluding non-cutaneous skin cancer, and is the third most common cause of cancer related deaths among this cohort. The most utilised …
-
A Computational and Mathematical Approach to the Preclinical Development of Alpha Emitting Radiopharmaceutical Therapies
… ion indicated for treatment of bone metastatic castrate resistant prostate cancer, irradiates lesions through targeted uptake in bone at sites of disease. We have undertaken the first Monte Carlo dosimetry studies of Radium-223 dose distribution based on primary patient-derived specimens. This …
-
Θεραπεία με 223-Radium Dichloride σε ασθενείς με ευνουχο-άντοχο (castrate-resistant) καρκίνο προστάτη, με επώδυνες οστικές μεταστάσεις και με απουσία σπλαχνικών μεταστάσεων
… αδενοκαρκινώματος του προστάτη αδένος( CRPC-castrate resistant prostate cancer). Ο υποψήφιος προς χορήγηση ασθενής θα πρέπει να πληροί αιματολογικά κριτήρια, όσον αφορά τον απόλυτο αριθμό ουδετερόφιλων ,αιμοπεταλίων και της αιμοσφαιρίνης ,για να ξεκινήσει τη θεραπεία. Η κύρια οδός αποβολής …
-
Development of an in vitro assay for high-throughput screening investigating the role of mesenchymal stem cells on castration resistant prostate cancer cell growth
… therapy (ADT) can increase survival from prostate cancer by up to 2-3 years, but tumours invariably relapse into an ADT-unresponsive, incurable form, known as castrate resistant prostate cancer (CRPC). CRPC is more aggressive and more likely to metastasise to bone, worsening morbidity and …
-
Characterisation of Androgen Receptor Signalling and Metabolism in Prostate Cancer
Prostate cancer (PCa) is a prevalent disease which affects men worldwide. The Androgen Receptor (AR) is responsible for driving disease progression, therefore therapies often target this signalling axis. Eventually, these treatments fail and the cancer progresses to an aggressive, incurable stage …
-
The Development of Gene Therapy by way of DNAzymes, and a Computational Tool that Predicts Efficient DNAzymes.
Prostate cancer (PCa) is the second highest cause of male cancer related death in the UK. The majority of aggressive cases of PCa spread outside of the organ to areas such as the bone where it becomes difficult to treat. Current treatment options focus on targeting androgens, the male sex hormones. …
-
Autophagy as a Survival Mechanism for Tumor Cells Exposed to Chemotherapy or Hypoxia, and its Inhibition by Pantoprazole to Improve Outcome of Treatment
… used as treatment for patients with metastatic cancer, and is also used to prevent disease recurrence and metastatic spread after local treatment. Autophagy allows recycling of cellular components and may facilitate cell survival after chemotherapy. The clinically used proton pump inhibitor …
Page 1 of 3